en · de · es · fr · pt
tb-500-notes.peptides5388.com › Guide › Tb-500 Identity And Chemical Background — Research Overview

Tb-500 Identity And Chemical Background — Research Overview

By Editorial Desk · published 2026-02-01 · last reviewed 2026-03-22 · Guide

peptide fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-03-22. Where a claim depends on a specific study, the study is described rather than over-claimed.

TB-500 Identity and Chemical Background

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

Detection, Stability, and Regulatory Status

Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.

Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.

Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.

Tb-500 at a glance

PropertyValueNotes
Physical formLyophilised powderSealed vial; reconstituted before laboratory use
AppearanceWhite to off-white solidVisual descriptor used on certificates of analysis
Solubility classWater-solubleDissolves in water and aqueous buffers
Reported mass, fragmentNear 889 DaValue depends on the stated sequence
Reported mass, parent proteinNear 4963 Da43-residue thymosin beta-4

Identity and Reported Background

Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.

Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.

Related pages on this site

TB-500 Background and Identity

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Reference notes

==== Clinical effects ==== The total endometrial proliferation dose of sublingual estradiol in women is 60 to 140 mg per cycle or 14 days and of sublingual estradiol benzoate in women is 60 to 180 mg per cycle or 14 days. Both sublingual estradiol and sublingual estradiol benzoate have a persistence of estrogenic effect after a dose of only one day. The effects of sublingual estradiol on gonadotropin levels have also been studied in postmenopausal women. After a dose of sublingual estradiol, levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) decrease precipitously within 4 hours. Following this, LH and FSH levels gradually increase, and return to near-baseline levels by 24 hours. One study found no difference between oral and sublingual estradiol in suppression of LH levels. However, FSH levels were suppressed to a greater extent with sublingual estradiol than with oral estradiol in the study. It is notable that the magnitude of the genomic effects of estradiol (i.e., signaling through the nuclear ERs) may, at least in some cases, be dependent on the total estrogenic exposure as opposed to the duration of exposure. For instance, in normal human epithelial breast cells and ER-positive breast cancer cells, the rate of breast cell proliferation has been found not to differ with estradiol incubation of 1 nM for 24 hours and incubation of 24 nM for 1 hour.

However, the mobilization against the "peace process", as its defenders called it, did not prevent the government from initiating contacts with the ETA leadership. To put pressure on the government, ETA intensified street fighting (kale borroka) and finally on December 30, 2006, T-4 bombing placed a powerful bomb in the T-4 terminal of Barajas airport which caused the death of two people and enormous material damage. The government considered the "peace process" "suspended" and on June 4, ETA announced the end of the truce. Attacks were resumed and members of ETA and Batasuna were arrested. Likewise, the process of illegalization of the Communist Party of the Basque Homelands and Basque Nationalist Action began. In response ETA murdered in cold blood a former socialist councilman in the Gipuzkoan town of Mondragón on the eve of the March 2008 general election.

== Research and career == Okan worked as a research fellow for one year at the Cleveland Clinic, USA. He studied wound care after laser resurfacing. He participated in the clinical and research activities of the Cleveland Clinic Florida Dermatology Department, published several clinical research articles and conducted clinical research projects. His research interest has focused on psoriasis, vitiligo, rosacea, laser and dermatologic signs of systemic diseases and wound healing. In April 2015, Okan published a popular book about dermatology, "Krem-Cilt Sağlığının ABC'si" ("Cream: The ABC's of Skin Care"). The book reflects day-to-day clinical experience and direct knowledge of cutting edge advances, advising people to choose cosmetic products carefully, and to maintain proper nutrition and hydration. He particularly advises parsley, nettle, chamomile, ginseng, thyme, melon, broccoli, and carrot, as well as Vitamin A, Vitamin B3, Vitamin C, Vitamin D, Vitamin K, Vitamin H, zinc and iron. In other media, Okan has also deemed a good-quality sunscreen to be the best defense against aging. Later in 2015, he participated in 23rd World Congress of Dermatology, in Vancouver. Okan is a European Board Certified dermatologist and passed the Specialty Certificate Examination (SCE) in Dermatology in the UK.

Sources: en.wikipedia.org

Notes from published material

=== Other characters === Toko Miura as Chiyoko Shimakura, a singer whose career becomes connected to Kazuko and Hotta. Yuko Nakamura as Mirei Sei, a fortune teller who influences Kazuko's later career. Shingo Mizusawa as a street vendor (episode 1). Hiccorohee as Mai (episode 1). Kimiko Yo as Kiyo Mita (episodes 2–3), Marohiko's mother and the head of the Mita household. Miwako Ichikawa as Towako Kato (episodes 8–9), Masataka Yasunaga's daughter. Show Kasamatsu as Osamu Miyazawa, Minori Uozumi's ex-husband (episode 8). Kaho Tsuchimura as a mistress (episodes 8–9). Toshie Negishi as Minori Uozumi's mother. Nagomu Miyamoto as Nobu Murao. Razor Ramon HG as himself

=== Treatment === Pentosan polysulfate (PPS) may slow the progression of the disease, and may have contributed to the longer than expected survival of the seven people studied. The CJD Therapy Advisory Group to the UK Health Departments advises that data are not sufficient to support claims that pentosan polysulfate is an effective treatment and suggests that further research in animal models is appropriate. A 2007 review of the treatment of 26 people with PPS finds no proof of efficacy because of the lack of accepted objective criteria, but it was unclear to the authors whether that was caused by PPS itself. In 2012 it was claimed that the lack of significant benefits has likely been caused because of the drug being administered very late in the disease in many patients. Use of RNA interference to slow the progression of scrapie has been studied in mice. The RNA blocks the production of the protein that the CJD process transforms into prions. Both amphotericin B and doxorubicin have been investigated as treatments for CJD, but as yet there is no strong evidence that either drug is effective in stopping the disease. Further study has been conducted with other medical drugs, but none are effective. However, anticonvulsants and anxiolytic agents, such as valproate or a benzodiazepine, may be administered to relieve associated symptoms. Quinacrine, a medicine originally created for malaria, has been evaluated as a treatment for CJD.

=== Autumn 2007: Deaths across north Texas === The spread of the drug to the outlying suburbs of Dallas was confirmed in September by the return of toxicology reports from the July 13 death of an 18-year-old student from McKinney, located northeast of Dallas in Collin County, and from two July deaths in nearby Tarrant County, one involving a 17-year-old male and the other, a 26-year-old male. Additional suburban deaths in September — in Irving to the west and Rockwall to the east — were believed to be linked to cheese heroin, though police cautioned toxicology reports would not likely be complete until November. The Tarrant County medical examiner's office announced on September 24 that a review of deaths in Tarrant County (west) and Denton County (north) showed an additional 15 deaths between 2004 and 2007 that appeared to be linked to "cheese," and Collin and Rockwall counties had reported one death each. These new figures brought the total number of deaths associated with cheese heroin in northern Texas to 40, a figure that included many older adults along with those age 18 and under.

Sources: en.wikipedia.org

Background from the literature

University at Buffalo School of Medicine and Biomedical Sciences, also known as Jacobs School of Medicine and Biomedical Sciences, is a public medical school in the city of Buffalo, New York, at the University at Buffalo. Founded in 1846, it is one of the oldest medical schools in the United States and is the only medical school in Buffalo. It is part of the State University of New York (SUNY) system. It offers degrees in various field such as Biomedical Sciences undergraduate majors, Biotechnical and Clinical, Laboratory Sciences, Master's programs in Biomedical Sciences, PhD programs in Biomedical Sciences, MD program, Graduate Medical Education residency program, Continuing Medical Education, postdoctoral programs, as well as dual-degree programs.

In various diseases, such as type II diabetes, metabolic syndrome, and cancer, normal metabolism is disrupted. The metabolism of cancer cells is also different from the metabolism of normal cells, and these differences can be used to find targets for therapeutic intervention in cancer.

Early sowing of seeds and deep plowing of poppy residues can reduce fungal inoculum during the plant growing season in the following year on neighboring poppy stocks, respectively. Mosaic diseases in P. somniferum are caused by rattle virus and the Carlavirus. In 2006, a novel virus tentatively called "opium poppy mosaic virus" (OPMV) from the genus Umbravirus was isolated from P. somniferum containing leaf mosaic and mottling symptoms, in New Zealand.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.

Why do product listings show different sequences?

Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.

What is the reported molecular mass?

The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.

How is the peptide detected in samples?

The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.

Network